Treatment of the pruritus of cholestasis

Current Treatment Options in Gastroenterology

Volumn 7, Issue 6, 2004, Pages 501-508

  Bergasa, Nora V ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANION EXCHANGE RESIN; ANTICOAGULANT AGENT; BILE ACID; BUTORPHANOL; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CHOLESTEROL; COLESEVALAN; COLESTIPOL; COLESTYRAMINE; DIGITALIS; DRONABINOL; KAPPA OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR ANTAGONIST; NALOXONE; NALTREXONE; ONDANSETRON; OPIATE ANTAGONIST; PLACEBO; PROPRANOLOL; RIFAMPICIN; SEROTONIN 3 RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TETRACYCLINE; THIAZIDE DIURETIC AGENT; THYROXINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

ABDOMINAL DISCOMFORT; AEROSOL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILE; BIOSYNTHESIS; BLOOD LEVEL; CHOLESTASIS; CLINICAL OBSERVATION; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIET THERAPY; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG ABUSE; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REGIMEN; DRUG RESPONSE; DRUG TOLERABILITY; DRUG USE; ENDOSCOPIC SURGERY; FECES; HEMODIALYSIS; HUMAN; HYPERCHLOREMIC ACIDOSIS; HYPERTRIGLYCERIDEMIA; LIFESTYLE; LIVER; LIVER TOXICITY; MALABSORPTION; NOCICEPTION; PATHOGENESIS; PATIENT SELECTION; PRESCRIPTION; PRURITUS; SEROTONINERGIC SYSTEM; SIDE EFFECT; WITHDRAWAL SYNDROME;

EID: 9744278324     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-004-0009-1     Document Type: Article

References (27)

1. Bergasa NV: Pruritus in chronic liver disease: mechanisms and treatment. Curr Gastroenterol Rep 2004, 6:10-16.
2. Jinks SL, Carstens E: Superficial dorsal horn neurons identified by intracutaneous histamine: chemonociceptive responses and modulation by morphine. J Neurophysiol 2000, 84:616-627.
3. Jones EA, Bergasa NV. The pruritus of cholestasis: from bile acids to opiate agonists. Hepatology 1990, 11: 84-887.
4. Thornton JR, Losowsky MS: Opioid peptides and primary biliary cirrhosis. British Medical Journal 1988, 297: 501-1504.
5. Bergasa NV, Sabol SL, Young WS 3rd, et al.: Cholestasis is associated with preproenkephalin mRNA expression in the adult rat liver. Am J Physiol 1995, 268:G346-G354.
6. Bergasa NV: Hepatic Met-enkephalin immunoreactivity is enhanced in primary biliary cirrhosis. Liver 2002, 22: 07-113.
7. Dagenais C, Ducharme J, Pollack GM: Uptake and efflux of the peptidic delta-opioid receptor agonist. Neurosci Lett 2001, 301:155-158.
8. Datta DV, Sherlock S: Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology 1966, 50:323-332.
9. Berg C: Use of colesevelam hydrochloride (Welchol ) as a novel therapeutic agent for the management of refractory pruritus in chronic liver disease. Hepatology 2001, 34:541.
10. Bergasa NV, Alling DW, Talbot TL, et al.: Naloxone ameliorates the pruritus of cholestasis: results of a double-blind randomized placebo-controlled trial. Annals of Internal Medicine 1995, 123:161-167.
11. Wolfhagen FH, Sternieri E, Hop WC, et al.: Oral naltrex-one treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997, 113: 264-1269.
12. Terg R, Coronel E, Sorsa J, et al.: Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis. J Hepatol 2002, 37:717-722.
13. Bachs L, Parés A, Elena M, et al.: Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992, 102:2077-2080.
14. Mullally BA, Hansen WF: Intrahepatic cholestasis of pregnancy: review of the literature. Obstet Gynecol Surv 2002, 57:47-52.
15. Ko MC, Lee H, Song MS, et al.: Activation of kappa-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administration of morphine in monkeys. J Pharmacol Exp Ther 2003, 305:173-179.
16. Richardson BP: Serotonin and nociception. Annals of the New York Academy of Science 1990, 600:511-520.
17. Schworer H, Hartmann H, Ramadori G: Relief of cholestatic pruritus by a novel class of drugs: 5- hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995, 61:33-37.
18. O'Donohue JW, Haigh C, Williams R: Ondansetron in the treatment of the pruritus of cholestasis: a randomised controlled trial. Gastroenterology 1997, 112:1349.
19. Neff GW, O'Brien CB, Reddy KR, et al.: Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol 2002, 97:2117-2119.
20. Gingold A, Bergasa NV. The cannabinoid agonist WIN 55, 212-2 increases nociception threshold in cholestatic rats: implications for the treatment of the pruritus of cholestasis. Lifie Sciences 2003, 73:2741-2747.
21. Ghent CN, Carruthers SG: Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988, 94:488-493.
22. Emerick KM, Whitington PF: Partial external biliary diversion for intractable pruritus and xanthomas in Alagille syndrome. Hepatology 2002, 35:1501-1506.
23. Ng VL, Ryckman FC, Porta G, et al.: Long-term outcome after partial external biliary diversion for intractable pruritus in patients with intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 2000, 30:152-156.
24. Stange J, Hassanein TI, Mehta R, et al.: The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif Organs 2002, 26:103-110.
25. Doria C, Mandala L, Smith L et al.: Effect of molecular adsorbent recirculating system in hepatitis C virus-related intractable pruritus. Liver Transpl 2003, 9:437-443.
26. Moore RY. Organization of the mammalian circadian system. In Circadian Clocks and Their Readjustments. Edited by Chadwick DJ, Ackrill K. London: John Wiley & Sons; 1993:88-106.
27. Bergasa NV, Link MJ, Keogh M, et al.: Pilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease. Am J Gastroenterol 2001, 96: 563-1570.